(KTTA) Pasithea Therapeutics Corp. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KTTA) Pasithea Therapeutics Corp. Complete Analysis Pack
Unlock Strategic Clarity
This Pasithea Therapeutics Corp. 4P's Marketing Mix Analysis explains the company’s product offerings, pricing approach, distribution channels, and promotional tactics in a concise, actionable format; the page shows a real preview/sample of the analysis so you can review style and content before buying. Purchase the full version to receive the complete ready-to-use report.
Product
Psychiatric and neurological therapeutics R&D
Pasithea Therapeutics Corp.'s core product is its development-stage psychiatric and neurological therapeutics R&D pipeline, so the product is not a single drug but a set of novel candidates in discovery and clinical development. As of July 2026, this remains the company’s main offering, with value tied to pipeline progress, trial data, and regulatory milestones rather than current product sales.
Novel therapeutic candidates
Pasithea Therapeutics Corp. is a pre-commercial biotech, so its main product is its pipeline, not a sold consumer drug. Its novel therapeutic candidates target unmet mental health and neuro-related needs, which is the core of its value proposition. In 2025 filing terms, this means the company’s product value is tied to R&D progress, clinical milestones, and cash burn rather than sales volume.
Depression treatment clinics
Pasithea Therapeutics Corp. plans depression treatment clinics to move beyond drug discovery and into direct care. Depression affects about 280 million people worldwide, and major depressive disorder has high repeat-visit demand, so a clinic model can support steady treatment delivery and recurring revenue. It also gives Pasithea a live channel to pair its drugs with physician-led care.
IV ketamine infusion service
Pasithea Therapeutics Corp.’s IV ketamine infusion service is a clinic-based, physician-supervised treatment for depression, usually delivered as 0.5 mg/kg over about 40 minutes. In treatment-resistant depression, ketamine has shown rapid symptom relief within 24 hours in many studies, with response rates often near 50% to 70%.
- Service-based, clinical administration
- Requires supervised infusion setting
- Targets depression care demand
- Protocol often uses 6 sessions
Pharmacist-administered care
Pasithea Therapeutics Corp.’s pharmacist-administered care adds a controlled service layer to its clinic mix: trained pharmacists give intravenous ketamine infusions, which tightens dose control and monitoring in a 40-minute treatment setting. In practice, this supports safer delivery and a more standardized patient experience.
- Trained pharmacists administer IV ketamine
- Controlled clinic-based delivery
- Supports dose control and monitoring
Pasithea’s Pipeline Plays on Big Need, Not Current Sales
Pasithea Therapeutics Corp.’s Product is its pre-commercial psychiatry and neurology pipeline, so value still depends on trial data, not sales. Its clinic layer adds IV ketamine for depression, a physician-supervised service typically given at 0.5 mg/kg over about 40 minutes. The model targets a large need: depression affects about 280 million people worldwide and ketamine studies often show 50% to 70% response rates in treatment-resistant cases.
| Product | Key data |
|---|---|
| Pipeline | Pre-commercial; R&D-led |
| IV ketamine clinic | 0.5 mg/kg; 40 min |
| Market need | 280 million with depression |
| Clinical signal | 50% to 70% response |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Pasithea Therapeutics Corp. that maps Product, Price, Place, and Promotion into clear strategic insights.
Editable Excel File
Condenses Pasithea Therapeutics’ 4Ps into a quick, clear snapshot for fast alignment and easier decision-making.
Reference Sources
Provides a concise bibliography linking Pasithea Therapeutics' clinical data, SEC filings, industry reports, and peer-reviewed studies to each key market, pricing, and competitive claim.
Place
Miami Beach, Florida headquarters
Pasithea Therapeutics Corp.'s Miami Beach, Florida headquarters is its main corporate base, where management, administration, and business oversight are centered. The company reported 11 full-time employees in its 2025 proxy filing, so this location supports a lean operating model. Keeping leadership in Miami Beach helps coordinate strategy, finance, and compliance from one site.
Clinic-based delivery model
Pasithea Therapeutics Corp. uses a clinic-based delivery model for its depression treatment, so patients receive care in physical healthcare sites, not retail channels. That fits in-person monitoring, which matters in depression care where U.S. major depressive disorder affects about 21 million adults each year. The model supports higher-touch treatment and follow-up, but it also limits reach to patients who can travel to a clinic.
Direct patient access
Patients receive Pasithea Therapeutics Corp. care through clinic visits, creating a direct-to-patient service channel. This works well for supervised procedures like IV infusions, where staff can monitor vital signs and dosing on site.
In 2025, U.S. outpatient clinics still handled most infusion-based specialty care, so this model fits treatments that need close medical oversight and fast response to side effects.
Healthcare facility setting
Pasithea Therapeutics Corp. delivers ketamine-based treatment in a medical facility, where trained staff can monitor vital signs, dosing, and adverse effects in real time. That setting fits ketamine’s need for controlled administration and patient safety, especially because the medicine can affect blood pressure and alertness. In this type of care, the clinic is not just a site; it is part of the treatment model.
- Monitored dosing and vital signs
- Safer response to side effects
- Matches ketamine care rules
U.S.-based operations
Pasithea Therapeutics Corp is a U.S. company based in Florida, so its clinic plan sits inside domestic healthcare rules and payer systems. That matters because patient access, referrals, and drug delivery all move through regulated medical channels, not open retail routes.
- U.S.-only clinic footprint
- Florida operating base
- Distribution via medical channels
- Tied to domestic healthcare infrastructure
Miami Beach Base Shapes Pasithea’s Clinic-Only Reach
Pasithea Therapeutics Corp. keeps Place centered on its Miami Beach, Florida base, with 11 full-time employees in its 2025 proxy filing. Its care is delivered through U.S. clinic visits, which fits monitored ketamine treatment and direct patient oversight.
This clinic-only footprint supports safety, but it also limits access to patients who can travel. U.S. major depressive disorder affects about 21 million adults a year, so the site choice ties reach to domestic medical channels.
| Place factor | Data point |
|---|---|
| Headquarters | Miami Beach, Florida |
| Full-time employees | 11 in 2025 proxy |
| Delivery channel | U.S. clinic-based care |
| Market need | About 21 million U.S. adults with MDD yearly |
What You See Is What You Get
Pasithea Therapeutics Corp. Reference Sources
The preview shown here is the exact, full Pasithea Therapeutics Corp. 4P's Marketing Mix analysis you’ll receive instantly after purchase—no mockups or samples.
This ready-made document is complete, editable, and ready for immediate use in strategy, investor decks, or due diligence.
Buy with confidence: the file you see is the real deliverable you'll download at checkout.
Promotion
Public-company disclosure
Pasithea Therapeutics Corp. uses SEC filings and other required disclosures as a core promotion channel for investors. In its latest 2025–2026 reports, it spells out strategy, operations, cash use, and risk factors, which helps the market track the business without paid ads. This matters more for a small public company where filing updates often drive investor attention.
Press releases
Pasithea Therapeutics Corp. uses press releases to announce research progress, clinic plans, and key corporate updates, giving investors and partners a fast read on company moves.
This matters because small biotech firms often rely on news flow to build awareness and support visibility before revenue ramps.
Each release can shape market attention around trial milestones, site openings, and strategic changes.
Clinical update messaging
Pasithea Therapeutics Corp. uses clinical update messaging to spotlight pipeline milestones and explain its scientific direction. Clear progress updates on therapeutic development build trust in biotech markets, especially when the company is advancing early-stage assets and trial work. For investors, these messages matter because they turn research steps into visible proof of execution.
Investor communications
Pasithea Therapeutics Corp. must use investor communications to explain its pipeline, funding needs, and trial milestones, because development-stage biotech firms usually live on market trust, not sales. Clear updates on cash runway, capital raises, and execution can keep shareholders engaged and support attention from analysts.
- Show funding needs early.
- Link spending to milestones.
- Update on trial progress.
- Keep market trust active.
For Pasithea Therapeutics Corp., this is the main way to frame risk and keep capital access open.
Corporate website messaging
Pasithea Therapeutics Corp. should use its corporate website to explain its pipeline and clinic model in one place, so investors and patients can quickly compare programs, care access, and trial updates. As of its latest public filings, the Company has reported cash needs typical of a development-stage biotech, so clear web messaging can support trust and outreach while reducing friction in investor due diligence.
- One source for pipeline and clinic details
- Supports brand visibility and outreach
- Helps investors track progress faster
Pasithea’s Investor-Driven Promotion: Cash, Trials, and Milestones
Pasithea Therapeutics Corp.’s Promotion is investor-led: SEC filings, press releases, clinical updates, and the website carry most of the message. In 2025–2026, these channels helped explain cash use, pipeline progress, and trial milestones, which matters for a development-stage biotech with limited product revenue.
| Channel | Role |
|---|---|
| SEC filings | Risk and cash disclosure |
| Press releases | Milestone visibility |
Price
No disclosed list price
Pasithea Therapeutics Corp. has no disclosed list price because it does not yet sell a broadly marketed, approved drug. Its value is still tied to development-stage assets and clinical services, so there is no standard consumer price to publish. In 2025/2026, the pricing story is still binary: trial-stage data, not a public drug label, drives value.
Precommercial pricing model
Pasithea Therapeutics Corp. uses a precommercial pricing model, so its price is not set for a mass-market launch. With no approved product sales, value is tied to R&D and clinical progress, not unit pricing; in fiscal 2025 the company still operated at a net loss and depended on external capital. That means pricing is driven by pipeline funding needs, not consumer demand.
Clinic service fees
Depression clinic care is priced like a medical service, so Pasithea Therapeutics Corp. is more likely to charge per visit or per infusion than use retail bundles. That fits an infusion model, where price usually tracks each treatment session and monitoring time. Exact fees are not publicly standardized in the information provided, so patients often need a direct quote.
Cash-pay and payer variability
Pasithea Therapeutics Corp. faces cash-pay and payer spread because ketamine-based depression care is priced by site, setting, and insurer rules. In the U.S., self-pay ketamine infusion visits are often quoted around $300 to $800, while initial psychiatric evaluations can add $200 to $500, so the final price can swing fast.
- Site and setting change the bill.
- Payer rules drive reimbursement gaps.
- Self-pay makes pricing highly variable.
Future approval-based pricing
Pasithea Therapeutics Corp. has no approved drug yet, so pricing is still development-stage and not set by market access or reimbursement. Once a candidate wins approval, pricing would shift to pharmaceutical pricing, where payer coverage and formulary access drive net price. For now, public price formation stays limited because there is no marketed product.
- No approval, no list price.
- Reimbursement sets net value.
- Access can cut gross price sharply.
Pasithea Has No Public List Price; Self-Pay Visits Vary Widely
Pasithea Therapeutics Corp. has no public list price in fiscal 2025/2026 because it still lacks a broadly marketed approved product. Pricing is service-based and site-specific, so cash-pay ketamine care can vary sharply; U.S. self-pay infusion visits often run $300-$800, with $200-$500 for an initial evaluation. Net price will depend on reimbursement after approval.
| Metric | 2025/2026 |
|---|---|
| List price | None disclosed |
| Self-pay visit | $300-$800 |
| Initial eval | $200-$500 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.